How life sciences organizations can reduce administrative barriers, improve coordination, and make expanded access programs more responsive to patient needs.
For patients with serious or life-threatening conditions who have exhausted available treatment options, expanded access may represent an important opportunity to receive an investigational therapy outside a clinical trial.
But between a physician's initial request and a patient's potential access to treatment lies a complex series of decisions, approvals, communications, and operational steps.
Each step serves a purpose. Pharmaceutical companies must evaluate medical eligibility, assess available drug supply, consider regulatory requirements, and ensure appropriate oversight. These safeguards are essential to responsible expanded access.
The challenge is that the processes connecting these steps are often fragmented, manual, and difficult to coordinate.
The next opportunity to improve expanded access may not be changing the regulatory pathway itself, but removing unnecessary friction from the processes that support it.
The Cumulative Impact of Small Delays
When pharmaceutical companies evaluate the efficiency of their expanded access programs, they often focus on major milestones: request submission, medical review, approval, and treatment initiation.
Yet some of the most consequential operational challenges occur between these milestones.
A physician submits a request but leaves out required information. A medical reviewer needs clarification. A regional team is waiting for confirmation of drug availability. An approval has been granted, but the next operational step has not been assigned.
Individually, these may appear to be minor administrative issues. Collectively, they can create delays and uncertainty.
For patients facing serious illnesses, time can be especially important.
This raises a critical question for pharmaceutical companies:
How much time in the expanded access process is spent making necessary medical and regulatory decisions, and how much is spent navigating avoidable administrative complexity?
Understanding that distinction is an important first step toward building more responsive programs.
Five Sources of Operational Friction in Expanded Access
1. Incomplete Requests Create Unnecessary Back-and-Forth
Expanded access often begins with a healthcare provider submitting a request for an investigational therapy.
Depending on the therapy, program, and country, the information required may vary significantly. When intake processes are inconsistent or insufficiently structured, requests can arrive with missing documentation or incomplete patient information.
This creates additional work for both the physician and the pharmaceutical company.
How MedaSystems helps: Configurable digital intake forms allow sponsors to standardize information collection while accommodating the requirements of different therapies, countries, and programs. Structured workflows help teams identify missing information earlier and reduce unnecessary follow-up.
2. Fragmented Communication Makes Coordination Difficult
Expanded access requests frequently involve multiple stakeholders, including Medical Affairs, Regulatory Affairs, Clinical Operations, supply chain teams, and external healthcare providers.
When communications are scattered across email threads, spreadsheets, and separate systems, teams may struggle to determine who is responsible for the next action or whether important information has already been shared.
The problem is not necessarily a lack of communication. It is a lack of shared visibility.
How MedaSystems helps: A centralized platform brings program information, request status, communications, and documentation into a shared environment. Role-based access and automated notifications help the appropriate stakeholders stay informed while maintaining appropriate controls over sensitive information.
3. Decision-Making Becomes More Difficult as Programs Expand
A program managing a handful of requests in one country faces different operational demands from a global program supporting multiple therapies and hundreds of healthcare providers.
Country-specific requirements, internal approval processes, medical eligibility criteria, and supply considerations introduce complexity.
Without clearly defined workflows, organizations may find it difficult to apply policies consistently across teams and regions.
How MedaSystems helps: Configurable workflows, automated assignments, and centralized program oversight help sponsors operationalize their policies across geographies and therapies. Teams can maintain consistent processes while allowing for necessary local variations.
4. Limited Visibility Makes It Hard to Identify Bottlenecks
Many organizations can report how many expanded access requests they have received or approved.
Fewer have an easily accessible view of where requests are slowing down, which activities require the most follow-up, or how operational performance varies across programs.
Without this information, process improvements may be based on anecdotal experience rather than measurable patterns.
How MedaSystems helps: Centralized dashboards, structured program data, and reporting capabilities help teams monitor activity, review request status, and identify potential bottlenecks.
With MedaSystems' emerging AI-enabled capabilities, including its Model Context Protocol (MCP) server in beta, authorized users can also explore program data through natural-language questions, supporting more accessible operational analysis.
5. Administrative Work Continues After Initial Approval
Expanded access does not end when a request is approved.
Depending on the program, teams may need to coordinate initial supply, manage resupply requests, collect follow-up information, document safety-related activities, and maintain appropriate records.
These ongoing responsibilities can create significant operational demands, particularly for programs supporting patients over extended periods.
How MedaSystems helps: Integrated workflows support activities throughout the program lifecycle, including supply and resupply coordination, follow-up data collection, documentation, and audit trails.
By keeping these activities connected, sponsors can reduce fragmented administration and maintain better continuity throughout treatment access.
From Managing Requests to Managing the Entire Access Journey
One of the most important shifts pharmaceutical companies can make is to stop viewing expanded access as a series of individual transactions.
A request is not simply a form to review or an approval to document. It is part of a larger journey involving multiple stakeholders, decisions, and responsibilities.
Optimizing one step while leaving the others disconnected may deliver only limited improvement.
A more effective approach considers the entire process:
Before submission: Make it easier for healthcare providers to understand requirements and provide complete information.
During evaluation: Give internal teams the information, visibility, and coordination tools needed to make informed decisions.
After approval: Support supply coordination, ongoing communications, and follow-up activities.
Across the program: Capture operational data that can reveal recurring challenges and opportunities for improvement.
This end-to-end perspective helps organizations move beyond simply processing requests toward building more connected and responsive expanded access programs.
A New Opportunity: Learning from Every Request
Expanded access programs generate valuable operational information.
Each request can provide insight into how the process is functioning: where clarification is frequently needed, which steps require additional coordination, and where resources may be constrained.
Historically, much of this information has remained buried in individual records, emails, or disconnected reporting systems.
Modern technology creates an opportunity to turn these operational details into actionable insights.
For example, program leaders may be able to identify recurring intake issues, compare workflow activity across regions, or recognize patterns that warrant further investigation.
AI-enabled analysis offers additional potential to make this information more accessible, allowing authorized teams to explore program activity without relying exclusively on manually generated reports.
The objective is not to automate medical judgment or replace regulatory oversight. It is to give the people responsible for these decisions better information and more time to focus on the work that requires their expertise.
When organizations can learn from the operational experience of each request, they are better positioned to improve the experience of the next one.
Making Expanded Access More Responsive Without Compromising Oversight
Speed and compliance are sometimes presented as competing priorities in expanded access.
But the goal should not be to eliminate necessary controls in pursuit of faster processing.
Instead, organizations should distinguish between activities that protect patients and ensure responsible decision-making, and administrative steps that introduce unnecessary work.
A well-designed digital platform can help support both objectives.
Standardized workflows promote consistency. Centralized documentation supports accountability. Role-based permissions and audit trails help maintain appropriate oversight. Automation reduces repetitive tasks while keeping responsible stakeholders involved.
The result is an operational foundation designed to support efficiency and governance together.
The Future of Expanded Access Is About Removing Friction
Expanded access will always require careful medical judgment, regulatory consideration, and responsible management of investigational therapies.
Technology cannot eliminate these responsibilities, nor should it.
What technology can do is make the processes surrounding those responsibilities more coordinated, transparent, and manageable.
At MedaSystems, we believe that reducing operational friction is an important part of making expanded access programs more effective.
Our platform helps life sciences organizations connect healthcare providers, internal teams, workflows, and program data in a secure, centralized environment designed to support Expanded Access, Post-Trial Access, and Investigator-Initiated Studies.
Because when a patient is waiting for a potential treatment option, every unnecessary administrative step is worth examining.
The future of expanded access isn't simply about processing more requests. It's about making every step of the access journey work better.
Ready to Reduce Friction in Your Expanded Access Programs?
Discover how MedaSystems helps pharmaceutical and biotechnology companies streamline workflows, improve collaboration, and manage expanded access programs with greater visibility and control.
